Author: Lynne Taylor

Physicians who have the least experience spend significantly more money treating patients than those who have the most experience, and this could have significant implications for recently-qualified doctors, US researchers have warned.

Sales of drugs to treat prostate cancer are set to more than double from 2011 to 2021, rising from a value of $4.1 billion to $9.1 billion over the period, according to new forecasts.

Perverse incentives in NHS funding structures have greatly increased the number of unnecessary admissions to hospitals in England over the last 10 years, by failing to encourage GPs and consultants to work together in the best interests of the patient, says new research from The Policy Exchange.

The total annual cost of all cancers to the UK economy is now £15.8 billion a year, and lung cancer accounts for £2.4 billion of this total – far more than any other form of the disease, says new research.

Generic drugmakers are predicted to be one of the big winners following US President Barack Obama’s return to the White House.